Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LRY018
MIFTS: 47

Laryngeal Squamous Cell Carcinoma

Categories: Cancer diseases, Oral diseases, Respiratory diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Laryngeal Squamous Cell Carcinoma

About this section

MalaCards integrated aliases for Laryngeal Squamous Cell Carcinoma:

Name: Laryngeal Squamous Cell Carcinoma 12 55 15
Epidermoid Carcinoma of the Larynx 12
Squamous Cell Carcinoma of Larynx 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases Skin diseases Oral diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2876
NCIt 50 C4044
UMLS 73 C0280324
Sources

Summaries for Laryngeal Squamous Cell Carcinoma

About this section
Disease Ontology : 12 A laryngeal carcinoma that has material basis in squamous cells.

MalaCards based summary : Laryngeal Squamous Cell Carcinoma, also known as epidermoid carcinoma of the larynx, is related to squamous cell carcinoma and intrahepatic cholangiocarcinoma. An important gene associated with Laryngeal Squamous Cell Carcinoma is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Endometrial cancer and Glioma. The drugs Cetuximab and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, skin and thyroid, and related phenotype is neoplasm.

Sources

Related Diseases for Laryngeal Squamous Cell Carcinoma

About this section

Diseases related to Laryngeal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.0 CCND1 CDKN2A CDKN2B-AS1 EGFR H19 HOTAIR
2 intrahepatic cholangiocarcinoma 30.2 CCAT1 EGFR TP53
3 larynx cancer 30.1 CCND1 CDKN2A EGFR MIR21 NME1 TERT
4 adenocarcinoma 30.0 CCND1 CDKN2A EGFR H19 MALAT1 TP53
5 thyroid cancer, nonmedullary, 1 29.9 H19 HOTAIR MALAT1 NEAT1
6 retinoblastoma 29.7 CCAT1 CCND1 CDKN2A HOTAIR MALAT1 TP53
7 melanoma 29.5 CDKN2A CDKN2B-AS1 H19 HOTAIR MALAT1 TP53
8 cholangiocarcinoma 29.3 CCND1 EGFR H19 MALAT1 MIR21 NEAT1
9 lung cancer susceptibility 3 29.2 CCAT1 CCND1 CDKN2A EGFR H19 HOTAIR
10 nasopharyngeal carcinoma 28.5 CCAT1 CCND1 CDKN2A CDKN2B-AS1 EGFR H19
11 breast papillomatosis 10.3 CCND1 CDKN2A
12 brain ependymoma 10.3 EGFR TP53
13 tonsil squamous cell carcinoma 10.3 CCND1 CDKN2A
14 male reproductive system disease 10.3 CCND1 TP53 VEGFA
15 bladder squamous cell carcinoma 10.3 CDKN2A TP53
16 papilloma 10.3
17 hypoxia 10.3
18 infiltrating angiolipoma 10.3 CDKN2A VEGFA
19 malignant peritoneal mesothelioma 10.3 CDKN2A EGFR
20 verrucous carcinoma 10.3 CCND1 CDKN2A TP53
21 keratinizing squamous cell carcinoma 10.3 CDKN2A TP53
22 inverted papilloma 10.3 CCND1 CDKN2A TP53
23 hidradenocarcinoma 10.3 CCND1 EGFR TP53
24 basaloid squamous cell carcinoma 10.3 CDKN2A EGFR TP53
25 retinal cancer 10.3 CCND1 CDKN2A TP53
26 pancreatic ductal carcinoma 10.3 CDKN2A TP53 VEGFA
27 vulva cancer 10.3 CDKN2A EGFR TP53
28 wilms tumor 2 10.3 H19 VEGFA
29 primary peritoneal carcinoma 10.3 EGFR TP53 VEGFA
30 bowenoid papulosis 10.3 CCND1 CDKN2A TERT
31 in situ carcinoma 10.3 CDKN2A EGFR TP53
32 ocular cancer 10.3 CCND1 CDKN2A TP53
33 anaplastic oligodendroglioma 10.2 CDKN2A EGFR
34 squamous cell papilloma 10.2 AURKA CDKN2A TP53
35 estrogen-receptor positive breast cancer 10.2 CCND1 EGFR TP53
36 breast carcinoma in situ 10.2 EGFR TP53 VEGFA
37 male reproductive organ cancer 10.2 CCND1 TP53 VEGFA
38 small cell carcinoma 10.2 CDKN2A EGFR TP53
39 ductal carcinoma in situ 10.2 CCND1 EGFR TP53
40 geographic tongue 10.2 EGFR NME1 VEGFA
41 malignant peripheral nerve sheath tumor 10.2 CDKN2A EGFR TP53
42 helicobacter pylori infection 10.2
43 skin melanoma 10.2 CDKN2A NME1 TP53
44 skin carcinoma in situ 10.2 CCND1 CDKN2A
45 li-fraumeni syndrome 10.2 CDKN2A EGFR TP53
46 differentiated thyroid carcinoma 10.2 EGFR TP53 VEGFA
47 spitz nevus 10.2 CDKN2A TP53
48 nasopharyngeal disease 10.2 CCND1 CDKN2A TP53 VEGFA
49 cervix disease 10.2 CCND1 CDKN2A TP53 VEGFA
50 uterine anomalies 10.2 CCND1 CDKN2A TP53 VEGFA

Graphical network of the top 20 diseases related to Laryngeal Squamous Cell Carcinoma:



Diseases related to Laryngeal Squamous Cell Carcinoma
Sources

Symptoms & Phenotypes for Laryngeal Squamous Cell Carcinoma

About this section

MGI Mouse Phenotypes related to Laryngeal Squamous Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 AURKA CCND1 CDKN2A EGFR NME1 TERT
Sources

Drugs & Therapeutics for Laryngeal Squamous Cell Carcinoma

About this section

Drugs for Laryngeal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
3
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
4
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
5
Bevacizumab Approved, Investigational Phase 3 216974-75-3
6
Fluorouracil Approved Phase 3,Phase 1 51-21-8 3385
7 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
8 Immunologic Factors Phase 3,Phase 2,Phase 1
9 Immunoglobulins Phase 3,Phase 2,Phase 1
10 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
11 Antibodies Phase 3,Phase 2,Phase 1
12 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
13 Micronutrients Phase 3,Phase 2
14 Vitamins Phase 3,Phase 2
15 Trace Elements Phase 3,Phase 2
16 Antimitotic Agents Phase 3,Phase 2
17 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
18 Immunoglobulin G Phase 3,Phase 2
19 Angiogenesis Inhibitors Phase 3,Phase 1
20 Antimetabolites Phase 3,Phase 2,Phase 1
21 Endothelial Growth Factors Phase 3
22 Mitogens Phase 3
23 Angiogenesis Modulating Agents Phase 3,Phase 1
24
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
25
Everolimus Approved Phase 2 159351-69-6 6442177
26
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
27
Pembrolizumab Approved Phase 1, Phase 2,Phase 2 1374853-91-4
28
Nelfinavir Approved Phase 2 159989-64-7 64143
29
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
30
Nivolumab Approved Phase 2 946414-94-4
31
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
32
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
33
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 6055-19-2, 50-18-0 2907
34
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
35
leucovorin Approved Phase 2 58-05-9 6006 143
36
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
37
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
38
Trioxsalen Approved Phase 2 3902-71-4 5585
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
40
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
41
Cediranib Investigational Phase 2 288383-20-0 9933475
42
Maleic acid Experimental Phase 2 110-16-7 444266
43
Tremelimumab Investigational Phase 1, Phase 2 745013-59-6
44 arginine Phase 2
45 Omega 3 Fatty Acid Phase 2
46 Soy Bean Phase 2
47 Anti-Bacterial Agents Phase 2,Phase 1
48 Antifungal Agents Phase 2
49 Antibiotics, Antitubercular Phase 2
50 Anti-Infective Agents Phase 2,Phase 1

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Recruiting NCT02236936 Phase 3 Cisplatin
2 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
3 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin Suspended NCT03258554 Phase 2, Phase 3
4 A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))
5 A Trial of Perioperative Immune Enhancing Feed in Patients Undergoing Surgery for Head and Neck Cancer Completed NCT01314755 Phase 2
6 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Completed NCT02007200 Phase 2 Soy Isoflavones
7 Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck Completed NCT01287390 Phase 2
8 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2 Temsirolimus
9 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2 Cediranib Maleate
10 A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma Recruiting NCT02759575 Phase 1, Phase 2 Pembrolizumab;Cisplatin
11 A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma Larynx Recruiting NCT02207439 Phase 2 Nelfinavir (Viracept®) 1250 mg
12 Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer Recruiting NCT03067610 Phase 2 chemotherapy
13 Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Recruiting NCT03342911 Phase 2 Paclitaxel;Carboplatin
14 Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Who Have Failed Platinum Based Therapy Recruiting NCT03468218 Phase 2 Cabozantinib
15 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery Recruiting NCT02734537 Phase 2 Cisplatin
16 Comparison of Adaptive Dose Painting by Numbers With Standard Radiotherapy for Head and Neck Cancer. Active, not recruiting NCT01341535 Phase 2
17 Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Active, not recruiting NCT01064479 Phase 2 Carboplatin;Cisplatin;Docetaxel;Erlotinib Hydrochloride
18 Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Active, not recruiting NCT00494182 Phase 2 Carboplatin;Paclitaxel;Sorafenib
19 IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma Not yet recruiting NCT03381183 Phase 1, Phase 2 Durvalumab;Tremelimumab;IRX-2 Regimen
20 A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy Terminated NCT01720563 Phase 2 Astragalus polysaccharides 500 mg;Placebo
21 Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Terminated NCT02196168 Phase 2 Cisplatin;WEE1 Inhibitor AZD1775
22 Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Terminated NCT01267240 Phase 2 Capecitabine;Vorinostat
23 Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer Terminated NCT02068157 Phase 2 Photodynamic Therapy;Porfimer Sodium
24 Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer Active, not recruiting NCT01254617 Phase 1 Lenalidomide
25 Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin Active, not recruiting NCT02381535 Phase 1 Cisplatin;Onalespib
26 Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer Active, not recruiting NCT01935921 Phase 1
27 Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT02775812 Phase 1 Cisplatin
28 Ganetespib Window of Opportunity Study in Head and Neck Cancers Terminated NCT02334319 Phase 1 Ganetespib
29 ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer Withdrawn NCT00006106 Phase 1 cisplatin;fluorouracil;ONYX-015
30 Altered and Conventional Fractionated Radiotherapy in Patients With Head and Neck Cancer Completed NCT00291434
31 Interest of Narrow Band Imaging in Detection of Upper Aerodigestive Cancers Completed NCT02035735 Not Applicable
32 Questionnaire in Screening Older Patients With Cancer Completed NCT00963911 Not Applicable
33 Nomograms to Precisely Predict Conditional Risk of Survival for Patients With Laryngeal Cancer Recruiting NCT03747783
34 Nomograms to Precisely Predict Conditional Risk of Recurrence for Patients With Laryngeal Cancer Recruiting NCT03595410
35 Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer Recruiting NCT03032250 Not Applicable
36 Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Recruiting NCT02582008 Early Phase 1 Bupropion Hydrochloride;Nicotine Replacement;Varenicline
37 Wound Complications in Head and Neck Surgery Enrolling by invitation NCT03134976 Levothyroxine
38 Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer Terminated NCT02388932 Not Applicable

Search NIH Clinical Center for Laryngeal Squamous Cell Carcinoma

Sources

Genetic Tests for Laryngeal Squamous Cell Carcinoma

About this section
Sources

Anatomical Context for Laryngeal Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Laryngeal Squamous Cell Carcinoma:

41
Lymph Node, Skin, Thyroid, Prostate, Endothelial, Lung, Neutrophil
Sources

Publications for Laryngeal Squamous Cell Carcinoma

About this section

Articles related to Laryngeal Squamous Cell Carcinoma:

(show top 50) (show all 864)
# Title Authors Year
1
To investigate the affiliation of XRCC-1 Gene Arg194Trp polymorphism in alcohol and tobacco substance users and loco-regionally progressed Laryngeal squamous cell carcinoma. ( 30370213 )
2019
2
Identification of gene expression models for laryngeal squamous cell carcinoma using co-expression network analysis. ( 29443735 )
2018
3
Tumor suppression effect of targeting periostin with siRNA in a nude mouse model of human laryngeal squamous cell carcinoma. ( 29978598 )
2018
4
Fibroblast growth factor receptor 1 amplification in laryngeal squamous cell carcinoma. ( 29351293 )
2018
5
Synchronous Laryngeal Squamous Cell Carcinoma and Intrahepatic Cholangiocarcinoma Present in an Obese Male with Poor Prognosis. ( 30194215 )
2018
6
MiR-613 suppressed the laryngeal squamous cell carcinoma progression through regulating PDK1. ( 29091303 )
2018
7
MicroRNA-26a inhibits proliferation and tumorigenesis via targeting CKS2 in laryngeal squamous cell carcinoma. ( 29143362 )
2018
8
Expression of DCUN1D1 in laryngeal squamous cell carcinoma and its inhibiting effect on TU-177 cells after interfered by RNA. ( 29164666 )
2018
9
Competing endogenous RNA network analysis of CD274, IL‑10 and FOXP3 co‑expression in laryngeal squamous cell carcinoma. ( 29257349 )
2018
10
Cetuximab enhances cisplatin-induced endoplasmic reticulum stress-associated apoptosis in laryngeal squamous cell carcinoma cells by inhibiting expression of TXNDC5. ( 29328423 )
2018
11
MiRNA-mRNA crosstalk in laryngeal squamous cell carcinoma based on the TCGA database. ( 29332170 )
2018
12
Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma. ( 29362129 )
2018
13
High expression of c-Met and EGFR is associated with poor survival of patients with glottic laryngeal squamous cell carcinoma. ( 29391895 )
2018
14
MicroRNA‑195 is associated with regulating the pathophysiologic process of human laryngeal squamous cell carcinoma. ( 29393451 )
2018
15
Long non-coding RNA AC026166.2-001 inhibits cell proliferation and migration in laryngeal squamous cell carcinoma by regulating the miR-24-3p/p27 axis. ( 29463827 )
2018
16
Role of epithelial-mesenchymal transition markers E-cadherin, N-cadherin, β-catenin and ZEB2 in laryngeal squamous cell carcinoma. ( 29467869 )
2018
17
Stromal versus tumoral inflammation differentially contribute to metastasis and poor survival in laryngeal squamous cell carcinoma. ( 29492204 )
2018
18
Oncologic and functional outcomes of pretreatment tracheotomy in advanced laryngeal squamous cell carcinoma: A multi-institutional analysis. ( 29496047 )
2018
19
Influence of anemia and BMI on prognosis of laryngeal squamous cell carcinoma: Development of an updated prognostic model. ( 29496054 )
2018
20
LZTS2 promoter hypermethylation: a potential biomarker for the diagnosis and prognosis of laryngeal squamous cell carcinoma. ( 29499699 )
2018
21
Human papillomavirus infection is not associated with laryngeal squamous cell carcinoma in Taiwan. ( 29500045 )
2018
22
Defining the regulatory role of programmed cell death 4 in laryngeal squamous cell carcinoma. ( 29510060 )
2018
23
Expression of long non-coding RNA HOXA11-AS is correlated with progression of laryngeal squamous cell carcinoma. ( 29511452 )
2018
24
Effects of the Akt inhibitor Src-homology 5 on proliferation and apoptosis of the laryngeal squamous cell carcinoma. ( 29516987 )
2018
25
YB-1 promotes laryngeal squamous cell carcinoma progression by inducing miR-155 expression via c-Myb. ( 29517281 )
2018
26
miR-181a targets GATA6 to inhibit the progression of human laryngeal squamous cell carcinoma. ( 29517349 )
2018
27
CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma. ( 29523110 )
2018
28
Expression of DNA-dependent protein kinase catalytic subunit in laryngeal squamous cell carcinoma and its importance. ( 29545847 )
2018
29
Comparative assessment of HPV, alcohol and tobacco etiological fractions in Algerian patients with laryngeal squamous cell carcinoma. ( 29563964 )
2018
30
Up-regulation of long non-coding RNA SNHG1 contributes to proliferation and metastasis in laryngeal squamous cell carcinoma. ( 29565491 )
2018
31
Recurrent transcriptional loss of the PCDH17 tumor suppressor in laryngeal squamous cell carcinoma is partially mediated by aberrant promoter DNA methylation. ( 29566279 )
2018
32
Oncologic outcomes of surgical treatment for T3 glottic laryngeal squamous cell carcinoma. ( 29601122 )
2018
33
Investigation of the SLC22A23 gene in laryngeal squamous cell carcinoma. ( 29703252 )
2018
34
Single nucleotide polymorphism rs11614913 associated with CC genotype in miR-196a2 is overrepresented in laryngeal squamous cell carcinoma, but not salivary gland tumors in Polish population. ( 29705927 )
2018
35
Laryngeal Squamous Cell Carcinoma Survival in the Context of Human Papillomavirus: A Systematic Review and Meta-analysis. ( 29713579 )
2018
36
Radiotherapy vs surgery for T1-2N0M0 laryngeal squamous cell carcinoma: A population-based and propensity score matching study. ( 29733513 )
2018
37
Long non-coding RNA LOC554202 promotes laryngeal squamous cell carcinoma progression through regulating miR-31. ( 29737563 )
2018
38
miR-196b is a prognostic factor of human laryngeal squamous cell carcinoma and promotes tumor progression by targeting SOCS2. ( 29753737 )
2018
39
Treatment delays in laryngeal squamous cell carcinoma: A national cancer database analysis. ( 29756382 )
2018
40
Long non-coding RNA biomarker for human laryngeal squamous cell carcinoma prognosis. ( 29775753 )
2018
41
MicroRNA-4497 functions as a tumor suppressor in laryngeal squamous cell carcinoma via negatively modulation the GBX2. ( 29843929 )
2018
42
MiR-125b-5p suppressed the glycolysis of laryngeal squamous cell carcinoma by down-regulating hexokinase-2. ( 29864898 )
2018
43
MiR-154 inhibits the growth of laryngeal squamous cell carcinoma by targeting GALNT7. ( 29874469 )
2018
44
Predictors of Thyroid Gland Invasion in Laryngeal Squamous Cell Carcinoma. ( 29876330 )
2018
45
Therapy Effects of Advanced Hypopharyngeal and Laryngeal Squamous Cell Carcinoma: Evaluated using Dual-Energy CT Quantitative Parameters. ( 29899458 )
2018
46
Whole-Transcriptome Analysis of CD133+CD144+ Cancer Stem Cells Derived from Human Laryngeal Squamous Cell Carcinoma Cells. ( 29949786 )
2018
47
Curcumin suppresses the progression of laryngeal squamous cell carcinoma through the upregulation of miR-145 and inhibition of the PI3K/Akt/mTOR pathway. ( 29950857 )
2018
48
MYO5A inhibition by miR-145 acts as a predictive marker of occult neck lymph node metastasis in human laryngeal squamous cell carcinoma. ( 29950866 )
2018
49
Decreased expression of protein tyrosine kinase 6 contributes to tumor progression and metastasis in laryngeal squamous cell carcinoma. ( 30029880 )
2018
50
Downregulation of CEACAM6 gene expression in laryngeal squamous cell carcinoma is an effect of DNA hypermethylation and correlates with disease progression. ( 30094098 )
2018
Sources

Variations for Laryngeal Squamous Cell Carcinoma

About this section

Cosmic variations for Laryngeal Squamous Cell Carcinoma:

9 (show top 50) (show all 319)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6927812 ZFHX3 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.4946C>T p.S1649F 16:72797736-72797736 10
2 COSM45571 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.593A>G p.E198G 17:7674938-7674938 10
3 COSM10662 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 10
4 COSM10995 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.580C>T p.L194F 17:7674951-7674951 10
5 COSM11066 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.578A>T p.H193L 17:7674953-7674953 10
6 COSM10714 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.473G>T p.R158L 17:7675139-7675139 10
7 COSM43690 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.592G>A p.E198K 17:7674939-7674939 10
8 COSM10905 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.451C>T p.P151S 17:7675161-7675161 10
9 COSM10779 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.818G>T p.R273L 17:7673802-7673802 10
10 COSM10888 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.378C>A p.Y126* 17:7675234-7675234 10
11 COSM10808 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.488A>G p.Y163C 17:7675124-7675124 10
12 COSM6549 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.743G>T p.R248L 17:7674220-7674220 10
13 COSM12559 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.673-2A>T p.? 17:7674292-7674292 10
14 COSM43846 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.487T>C p.Y163H 17:7675125-7675125 10
15 COSM10893 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.824G>A p.C275Y 17:7673796-7673796 10
16 COSM10659 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 10
17 COSM44475 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.871A>T p.K291* 17:7673749-7673749 10
18 COSM10813 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.394A>G p.K132E 17:7675218-7675218 10
19 COSM11462 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.388C>G p.L130V 17:7675224-7675224 10
20 COSM44219 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.405C>G p.C135W 17:7675207-7675207 10
21 COSM6906 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.672+1G>A p.? 17:7674858-7674858 10
22 COSM44067 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.721T>A p.S241T 17:7674242-7674242 10
23 COSM11658 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.955A>T p.K319* 17:7673573-7673573 10
24 COSM44071 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.955A>G p.K319E 17:7673573-7673573 10
25 COSM11305 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.809T>C p.F270S 17:7673811-7673811 10
26 COSM44352 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.850A>C p.T284P 17:7673770-7673770 10
27 COSM43583 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.425C>T p.P142L 17:7675187-7675187 10
28 COSM10889 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.536A>G p.H179R 17:7675076-7675076 10
29 COSM10758 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 10
30 COSM10660 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.818G>A p.R273H 17:7673802-7673802 10
31 COSM10777 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.715A>G p.N239D 17:7674248-7674248 10
32 COSM10742 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.578A>G p.H193R 17:7674953-7674953 10
33 COSM44456 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.668C>A p.P223H 17:7674863-7674863 10
34 COSM11166 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.406C>T p.Q136* 17:7675206-7675206 10
35 COSM10810 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.725G>T p.C242F 17:7674238-7674238 10
36 COSM43949 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.401T>G p.F134C 17:7675211-7675211 10
37 COSM43935 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.577C>A p.H193N 17:7674954-7674954 10
38 COSM10645 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.527G>T p.C176F 17:7675085-7675085 10
39 COSM44103 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.737T>A p.M246K 17:7674226-7674226 10
40 COSM10654 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.637C>T p.R213* 17:7674894-7674894 10
41 COSM44143 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.919+1G>A p.? 17:7673700-7673700 10
42 COSM10648 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 10
43 COSM44278 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.791T>C p.L264P 17:7673829-7673829 10
44 COSM43826 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.706T>A p.Y236N 17:7674257-7674257 10
45 COSM98254 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.782+1G>A p.? 17:7674180-7674180 10
46 COSM11374 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.752T>A p.I251N 17:7674211-7674211 10
47 COSM44678 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.415A>T p.K139* 17:7675197-7675197 10
48 COSM43947 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 17:7674917-7674917 10
49 COSM45544 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.947C>T p.P316L 17:7673581-7673581 10
50 COSM11081 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 10
Sources

Expression for Laryngeal Squamous Cell Carcinoma

About this section
Search GEO for disease gene expression data for Laryngeal Squamous Cell Carcinoma.
Sources

Pathways for Laryngeal Squamous Cell Carcinoma

About this section

Pathways related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 37
Show member pathways
 12.72 CCND1 CDKN2A EGFR TP53 VEGFA
2
Glioma 37
Show member pathways
 12.61 CCND1 CDKN2A EGFR TP53 VEGFA
3
Pathways in cancer 37
12.6 CCND1 CDKN2A EGFR TERT TP53 VEGFA
4
Gastric cancer 37
Show member pathways
 12.59 CCND1 CDKN2A EGFR TERT TP53
5
DNA Damage 4
12.36 AURKA CCND1 CDKN2A TP53
6
ErbB signaling pathway 1 37
Show member pathways
 12.33 CCND1 EGFR TP53 VEGFA
7
Human T-cell leukemia virus 1 infection 37
12.27 CCND1 CDKN2A TERT TP53
8
MicroRNAs in cancer 37
12.11 CCND1 CDKN2A EGFR MIR21 TP53 VEGFA
9
Proteoglycans in cancer 37
12.02 CCND1 EGFR MIR21 TP53 VEGFA
10
Colorectal Cancer Metastasis 64
11.95 CCND1 EGFR TP53 VEGFA
11
Integrated Breast Cancer Pathway 1
11.84 AURKA CCND1 EGFR TP53 VEGFA
12
Glioblastoma Multiforme 64
11.71 CCND1 CDKN2A EGFR TP53
13
Validated targets of C-MYC transcriptional activation 1
11.63 NME1 TERT TP53
14
Transcription Ligand-dependent activation of the ESR1/SP pathway 22
Show member pathways
 11.53 CCND1 EGFR VEGFA
15
Regulation of Telomerase 1
11.49 CCND1 EGFR TERT
16
HIF1Alpha Pathway 64
11.39 CDKN2A TP53 VEGFA
17
Hepatitis C and Hepatocellular Carcinoma 1
11.34 CCND1 TP53 VEGFA
18
Photodynamic therapy-induced AP-1 survival signaling. 1
10.96 CCND1 CDKN2A EGFR TP53
19
Bladder cancer 37 1
10.88 CCND1 CDKN2A EGFR TP53 VEGFA
20
LncRNA-mediated mechanisms of therapeutic resistance 1
10.65 HOTAIR TP53
Sources

GO Terms for Laryngeal Squamous Cell Carcinoma

About this section

Biological processes related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.88 CDKN2A CDKN2B-AS1 MIR21 TP53 VEGFA
2 positive regulation of cell migration GO:0030335 9.85 CDKN2B-AS1 EGFR MIR21 VEGFA
3 negative regulation of apoptotic process GO:0043066 9.85 AURKA EGFR MIR21 TERT TP53 VEGFA
4 positive regulation of protein phosphorylation GO:0001934 9.73 CCND1 EGFR MIR21 VEGFA
5 regulation of protein stability GO:0031647 9.71 AURKA CDKN2A TERT
6 cellular response to drug GO:0035690 9.69 EGFR NME1 TP53
7 positive regulation of epithelial cell proliferation GO:0050679 9.63 EGFR NME1 VEGFA
8 lactation GO:0007595 9.58 CCND1 NME1 VEGFA
9 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.52 EGFR TP53
10 liver regeneration GO:0097421 9.5 AURKA CCND1 EGFR
11 mitotic G1 DNA damage checkpoint GO:0031571 9.49 CCND1 TP53
12 cellular response to hypoxia GO:0071456 9.46 MALAT1 TERT TP53 VEGFA
13 response to UV-A GO:0070141 9.26 CCND1 EGFR
14 replicative senescence GO:0090399 9.13 CDKN2A TERT TP53
15 negative regulation of gene expression GO:0010629 9.1 CDKN2B-AS1 HOXA11-AS MIR21 NME1 TERT VEGFA

Molecular functions related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.02 AURKA CCND1 CDKN2A EGFR TP53
Sources

Sources for Laryngeal Squamous Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....